Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its position in Applied Therapeutics, Inc. (NASDAQ:APLT) by 11.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,653 shares of the company’s stock after buying an additional 4,507 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Applied Therapeutics were worth $908,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada grew its stake in shares of Applied Therapeutics by 403.2% in the 1st quarter. Royal Bank of Canada now owns 1,706 shares of the company’s stock valued at $32,000 after buying an additional 1,367 shares during the period. Nisa Investment Advisors LLC purchased a new stake in shares of Applied Therapeutics in the 2nd quarter valued at approximately $42,000. Citigroup Inc. grew its stake in shares of Applied Therapeutics by 53.6% in the 2nd quarter. Citigroup Inc. now owns 3,097 shares of the company’s stock valued at $64,000 after buying an additional 1,081 shares during the period. Deutsche Bank AG grew its stake in shares of Applied Therapeutics by 7.3% in the 2nd quarter. Deutsche Bank AG now owns 11,160 shares of the company’s stock valued at $232,000 after buying an additional 763 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Applied Therapeutics by 10.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,190 shares of the company’s stock valued at $233,000 after buying an additional 1,081 shares during the period. 58.69% of the stock is owned by institutional investors and hedge funds.

NASDAQ:APLT opened at $10.78 on Tuesday. The stock has a market cap of $282.61 million, a PE ratio of -2.60 and a beta of 0.92. The business’s 50 day moving average is $14.89. Applied Therapeutics, Inc. has a fifty-two week low of $10.22 and a fifty-two week high of $29.80.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings data on Friday, November 12th. The company reported ($1.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.15) by $0.06. Analysts forecast that Applied Therapeutics, Inc. will post -4.26 EPS for the current year.

Several research firms have recently weighed in on APLT. Zacks Investment Research raised shares of Applied Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 24th. Robert W. Baird reaffirmed a “buy” rating and set a $35.00 price objective on shares of Applied Therapeutics in a research report on Sunday, September 12th. Finally, The Goldman Sachs Group cut shares of Applied Therapeutics from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $16.00 to $10.00 in a research report on Thursday, August 26th.

About Applied Therapeutics

Applied Therapeutics, Inc operates as a clinical-stage biopharmaceutical company. The firm engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

See Also: Cyclical Stocks

Want to see what other hedge funds are holding APLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Therapeutics, Inc. (NASDAQ:APLT).

Institutional Ownership by Quarter for Applied Therapeutics (NASDAQ:APLT)